Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Lactose-free Memantine vs Ebixa in Healthy Subjects
NCT03670095Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Aug 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of memantine in Alzheimer's disease (AD) (2 arms), sponsored by Lundbeck. Primary endpoints: Area Under the Curve from 0 to 72 hours and Maximum Plasma Concentration. Started Aug 2018; status: completed.
02
Drugs
memantine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03670095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03670095.